Investment
Features
FeesSafety
Academy
More
Pluang+

Strategy ties next Bitcoin buy to STRC stock hitting $100 par value amid recent BTC sales and cash buildup.

Market News
16 Jul 2026
Crypto news
View Source
Neutral
pluang ai news

Strategy CEO Phong Le announced the company will resume buying Bitcoin once its preferred stock STRC recovers to the $100 par value, currently trading near $87. Strategy recently sold 3,588 BTC to build a $3 billion cash reserve, responding to shareholder demands for more liquidity. The STRC stock price below par limits Strategy's ability to raise funds efficiently for Bitcoin purchases. Meanwhile, MSTR stock faces resistance near $100–$105 with support around $90, indicating cautious investor sentiment as Strategy balances Bitcoin holdings and cash reserves.

More News

Medtronic beats Q3 earnings and revenue estimates, boosts outlook with $700M investment in Heart Tech and Robotics.

Medtronic beats Q3 earnings and revenue estimates, boosts outlook with $700M investment in Heart Tech and Robotics.

Medtronic reported Q3 earnings per share of $1.45, surpassing estimates of $1.39, and revenue of $9.76 billion, above the $9.55 billion consensus. The strong financial results reflect broad demand for its cardiovascular devices. The company raised it...

Company Fundamentals
Bullish
1 hour ago
Dell Technologies set for record Q2 earnings driven by AI server demand and strong revenue growth.

Dell Technologies set for record Q2 earnings driven by AI server demand and strong revenue growth.

Dell Technologies is expected to report record second-quarter earnings with EPS around $4.91 and revenue near $44.89 billion, fueled by high demand for its AI-optimized servers. This would mark a significant increase from last year's $29.78 billion a...

Company Fundamentals
Bullish
1 hour ago
Protagonist Therapeutics' price target raised to $180 after FDA approves new drug MIMRYLO.

Protagonist Therapeutics' price target raised to $180 after FDA approves new drug MIMRYLO.

Protagonist Therapeutics saw its stock price target raised to $180 by Barclays following the FDA approval of MIMRYLO, a first-in-class drug for polycythemia vera. The approval was based on strong Phase 3 trial results with 76.9% patient response, tri...

Analyst Insights
Bullish
2 hours ago
Hercules Capital upgraded to Buy by UBS, highlighting strong financials and 11.1% dividend yield.

Hercules Capital upgraded to Buy by UBS, highlighting strong financials and 11.1% dividend yield.

UBS upgraded Hercules Capital's rating from Neutral to Buy, reflecting confidence in the company's strong financial stability and growth prospects. Hercules Capital, a specialty finance firm supporting tech and life sciences startups, boasts a BBB+ c...

Analyst Insights
Bullish
3 hours ago
Seeking Alpha highlights 12 lesser-known stocks weekly to inspire fresh investment ideas.

Seeking Alpha highlights 12 lesser-known stocks weekly to inspire fresh investment ideas.

Seeking Alpha's "The Undercovered Dozen" is a weekly series that spotlights 12 lesser-covered stocks with market caps over $100 million and limited recent coverage. The series aims to introduce investors to overlooked investment opportunities, encour...

Others
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App